mRNA-1647
mRNA-1647 is Moderna's investigational cytomegalovirus (CMV) vaccine designed to protect against the most common cause of congenital viral infection in the United States. The vaccine encodes six CMV surface proteins — including the gH/gL pentameric complex — to elicit a broader immune response than prior single-antigen approaches that have failed in clinical trials. CMV infects roughly 1 in 200 infants born each year, causing permanent hearing loss and developmental disability; no CMV vaccine has ever been approved, making this the first Phase 3 efficacy trial for any CMV candidate.
Upcoming catalysts
Programs
Cytomegalovirus Infection
CMV is the most common cause of congenital infection in developed countries, affecting 1 in 200 live births and causing permanent hearing loss and developmental disability; no CMV vaccine has ever been approved despite decades of attempts, with all prior single-antigen candidates failing in efficacy trials. This Phase 3 program — the first efficacy trial for any CMV vaccine — tests mRNA-1647 in seronegative women aged 16–40, the population at highest risk of primary infection during pregnancy.